Dyne Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.2%projected annual EPS growth
Analyst Coverage
15analysts covering
FY EPS (est.)
-$3.57next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Expected Topline Data from ACHIEVE Registrational Expansion Cohort (REC) in DM1 | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly972.2MTarget: Sufficient to fund operations into Q1 2028
Dystrophin Expression (Muscle Content-Adjusted) in DELIVER Trial Annually5.5Target: Statistically significant increase relative to baseline to support Accelerated Approval
Watch Items
- FDA review and potential Accelerated Approval of z-rostudirsen (DYNE-251) in DMDTrigger: FDA acceptance of BLA and decision on Priority Review (6-month vs 10-month review)Action: Prepare commercial launch infrastructure for potential Q1 2027 U.S. launch
- Phase 3 HARMONIA trial enrollment and progress for z-basivarsen (DYNE-101) in DM1Trigger: Topline data from ACHIEVE Registrational Expansion Cohort (REC) in Q1 2027Action: Leverage REC data to support potential BLA submission for Accelerated Approval in Q3 2027
- Competitor clinical readouts (e.g., Avidity Biosciences' Phase 3 DM1 program)Trigger: Positive Phase 3 data from competitor del-desiranAction: Assess read-through to z-basivarsen and potential impact on accelerated approval timelines
Research as of 20 Jun 2026